Following this puts new work involving it at the top of your briefing, with a note saying why it is there. Links are taken from the source record, never inferred.
Real-world retrospective comparison showing lenvatinib superior to sorafenib on OS and treatment durability after first-line immunotherapy in HCC, but observational design and potential confounding limit strength of evidence.
This is a narrative review raising mechanistic questions about MET signaling in lung cancer immunology rather than reporting empirical results from original research.
Preclinical proof-of-concept in orthotopic xenograft models demonstrating paired radiotheranostic imaging and therapy, without clinical translation, comparative efficacy data, or power calculations.
A structured narrative review synthesizing pathophysiological mechanisms, drug hepatotoxicity profiles, and a proposed clinical management framework for treatment-related liver injury in HBV-associated HCC, intended to guide clinical decision-making.
A narrative review synthesizing early clinical trial data on an emerging technology without meta-analysis, formal quality assessment, or definitive efficacy endpoints; represents current state of evidence rather than practice-changing guidance.
A narrative synthesis of epidemiological trends and clinical management implications for HCC in Europe, intended to inform practice and policy rather than report a primary research finding.
A narrative review synthesizing surveillance recommendations, implementation challenges, and emerging approaches across geographies, offering expert consensus on HCC screening practice rather than primary evidence of clinical efficacy.
A single case report of advanced HCC with rupture treated with combination immunotherapy and successfully transplanted; demonstrates feasibility but lacks comparator, control group, and generalizability needed to establish efficacy or change practice.